Trial Profile

A Phase 1/2 dose escalation study assessing efficacy of Vobramitamab-duocarmazine duo in combination with lorigerlimab in patients with various advanced solid tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Nov 2024 According to a MacroGenics media release, until company completes its assessment of the monotherapy development opportunity for vobra duo in mCRPC, the Company has paused its other development efforts in alternative tumor types as well as the Phase 1/2 dose combination study of vobra duo plus lorigerlimab.
16 Aug 2023 New trial record
09 Aug 2023 According to MacroGenics media release, company will anticipates commencing the dose expansion portion of the study by year-end 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com